Introduction
Ischemia-reperfusion-induced neurological injury is a primary cause of stroke disability. Xenon (Xe), a bioactive gas, has potential as an effective and nontoxic neuroprotectant for the treatment of ischemic stroke [1] . When Xe is delivered by inhalation, high concentrations (50-70% v/v) are necessary to obtain a therapeutic effect, but limit the fraction of inspired oxygen. The goal of this work was to develop Xeloaded lipid-shelled microbubbles for site-specific release of Xe upon pulsed ultrasound exposure in the neurovasculature. By encapsulating Xe into micron-sized lipid-shelled microbubbles, the therapeutic gas can be shuttled through the vasculature until delivery is triggered by ultrasound exposure.
Methods
Xenon-loaded microbubbles (Xe-MBs) were synthesized by high-shear mixing of 1 ml lipid dispersion (9:1 molar ratio of DSPC and 18:0 PEG2000 PE) in a vial that contained 1 ml Xe, or a combination of Xe and octofluoropropane (OFP) (90/10% v/v), in the headspace. The size distribution and acoustic attenuation spectrum of XeMB were measured using a Coulter counter and broadband attenuation spectroscopy (over 2 -25 MHz), respectively [2] . Gas chromatography-mass spectrometry was employed to measure Xe dose. [3, 4] .
Results
Co-encapsulation of OFP increased the total volume, attenuation coefficient, and stability of microbubbles, shown in Figures 1 and 2 . Triggered release of the Xenon gas payload was demonstrated with 6-MHz duplex Doppler and 220-kHz pulsed ultrasound. The total Xe dose in Xe-MB and Xe-OFP-MB were 111.8 ± 16.1 and 127.0 ± 29.1 μl per mg of lipid, respectively, shown in Table 1 . 
Conclusions
These results motivate the continued investigation of lipid-shelled microbubbles for ultrasoundtriggered Xe delivery. Intravenous administration of microbubbles carrying a neuroprotective gas in combination with ultrasound exposure has potential as a novel noninvasive strategy for local therapeutic delivery to modulate the effects of cerebral ischemia. 
